A Worldwide Cancer Registry Enrolling Participants Profiled With a Next-Generation Sequencing Test

  • Cancer
  • Solid Tumors
Please note that the recruitment status of the trial at your site may differ.
Trial Status:

Recruiting

This trial runs in
Cities
  • Adana
  • Ankara
  • Asvestochori
  • Athens
  • bad-saarow
  • Bayrut
  • Bengaluru
  • Beograd
  • Besançon
  • Bogotá
  • Bratislavský kraj
  • Brest
  • Bristol
  • Buenos Aires
  • Cairo Governorate
  • Calgary
  • Cali
  • Cebu City
  • Chennai
  • Ciudad de México
  • Clermont-Ferrand
  • Dublin
  • Dublin 24
  • Dublin 4
  • Dublin 8
  • Edirne
  • Exeter
  • Golnik
  • Halle (Saale)
  • Hannover
  • Hanoi
  • Heilbronn
  • heroica-puebla-de-zaragoza
  • Hyderabad
  • İstanbul
  • Jerusalem
  • Johannesburg
  • Kaohsiung City
  • Krung Thep Maha Nakhon
  • Las Condes
  • Levallois-Perret
  • Lille
  • Lyon
  • Medellín
  • Mumbai
  • New Delhi
  • Ottawa
  • Palma
  • Paris
  • Pireas
  • Porto
  • Pretoria
  • Quimper
  • Rennes
  • Rio Grande do Sul
  • Riyadh
  • Saint-Priest-en-Jarez
  • Saint-Étienne
  • Santiago
  • Sremska Kamenica
  • Stuttgart
  • São Paulo
  • Taipei City
  • Tallinn
  • Taoyuan City
  • Tartu
  • Tel Aviv-Yafo
  • Thessaloniki
  • Thành phố Hồ Chí Minh
  • Torquay
  • Toulon
  • Villejuif
  • Warszawa
  • Wesel
  • Zaragoza
  • دبي
Trial Identifier:

NCT04529122 MX39897

      Show trial locations

      The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical trial see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.

      The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

      Results Disclaimer

      Trial Summary

      WAYFIND-R is a registry that aims to capture high-quality real-world data linking next-generation sequencing, treatments and outcomes from cancer patients diagnosed with a solid tumour. The WAYFIND-R has three main overarching objectives: 1. To provide a platform to support the design and conduct of clinical and epidemiological research; 2. To develop an evidence-generation platform to better understand health outcomes and cancer care processes; and 3. To characterize the treatments and clinical course of solid tumor cancers in patients who have undergone NGS testing.

      Hoffmann-La Roche Sponsor
      NCT04529122,MX39897 Trial Identifier
      Solid Tumours Condition
      Official Title

      A Registry to Collect Characteristics and Outcomes From Patients With Solid Tumors Profiled With a Next-Generation Sequencing Test (WAYFIND-R)

      Eligibility Criteria

      All Gender
      ≥18 Years Age
      No Healthy Volunteers
      Inclusion Criteria
      • Participant is an adult (according to the age of majority as defined by local regulations)
      • Participant is currently diagnosed with any type of solid tumour cancer, at any stage of the disease, at the enrollment date (informed consent date)
      • Participant has undergone NGS testing, no longer than 3 months prior to the enrollment date, irrespective of the availability of test results
      • Informed consent has been obtained from the participant or legally authorized representative, as per local regulations
      Exclusion Criteria
      • Participant has a prior or current diagnosis of haematological malignancy

      For the latest version of this information please go to www.forpatients.roche.com

       

      Related Trials

      Use our search to find other trials on Genentech Clinical Trials in related disease areas.

      Solid Tumors

      About Clinical Research

      What is a clinical trial? Why should I consider taking part in a clinical trial? And why does Genentech conduct clinical trials?

      Find out now